A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.

Meng, Fanying; Li, Wan-Fen; Jung, Donald; Wang, Chun-Chung; Qi, Tianyang; Shia, Chi-Sheng; Hsu, Ren-Yu; Hsieh, Yin-Cheng; Duan, Jianxin

Meng, Fanying; Li, Wan-Fen; Jung, Donald; Wang, Chun-Chung; Qi, Tianyang; Shia, Chi-Sheng; Hsu, Ren-Yu; Hsieh, Yin-Cheng; Duan, Jianxin.

Afiliação

Meng F; Ascentawits Pharmaceuticals, LTD Shenzhen, China.
Li WF; OBI Pharma, Inc. Taipei, Taiwan.
Jung D; Ascentawits Pharmaceuticals, LTD Shenzhen, China.
Wang CC; OBI Pharma, Inc. Taipei, Taiwan.
Qi T; Ascentawits Pharmaceuticals, LTD Shenzhen, China.
Shia CS; OBI Pharma, Inc. Taipei, Taiwan.
Hsu RY; OBI Pharma, Inc. Taipei, Taiwan.
Hsieh YC; OBI Pharma, Inc. Taipei, Taiwan.
Duan J; Ascentawits Pharmaceuticals, LTD Shenzhen, China.

Am J Cancer Res ; 11(7): 3645-3659, 2021.

Article em En | MEDLINE | ID: mdl-34354865

Palavras-chave

AKR1C3; alkylating agent; cancers and anti-cancer agent; prodrug

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google